New study now out in @ESMO_Open looking at #ScalpCooling outcomes in patients receiving trastuzumab deruxtecan for #MetastaticBreastCancer 🔓pubmed.ncbi.nlm.nih.gov/4225… @esalehiDNP @elmayermd @DrKateDibble @drsarahsam @NabihahTayob @stolaney1 #MBC #TDXd #BreastCancer #ColdCaps #ADCs

#ASCO26 Poster Session | Poster #117 | Long-term safety outcomes of pregnancy among young #BreastCancer survivors: Results from a prospective, multicenter cohort study. #AYA @KimiaSorouriMD @AnnPartridgeMD @ShoshRosenberg @DrKateDibble

Tune in tomorrow for an update on the efficacy of YES, an mHealth intervention for adolescent and young adults (#AYA). 🗓️ Sunday, May 31 ⏰ 8:00 - 8:06 AM CDT (9:00 - 9:06 AM EST) 📍 S403 @ShoshRosenberg @AnnPartridgeMD @DrKateDibble @NabihahTayob #asco26 #breastcancer

New @JAMANetworkOpen multicenter study on Extended Endocrine Therapy and Survival for #BreastCancer Subtypes in Premenopausal Patients. 🔓pubmed.ncbi.nlm.nih.gov/4208… @ValenzaCarmine @monicamilano84 @darioT_ @lorenzoguidimd @bianchitaM @DrKateDibble @elisabettasabet @curijoey @AnnPartridgeMD

Secondary outcomes from the YES trial will be presented tomorrow during Rapid Oral Session 1 at #ESMOBreast26. Tune if for an update on the efficacy of an mHealth intervention to address informational needs in adolescent and young adult (#AYA) #BreastCancerSurvivors. 🗓️ Thursday, May 7 ⏰ 09:54 - 09:59 CEST (3:54 - 3:59 AM EST) 📍 Berlin Hall @ShoshRosenberg @AnnPartridgeMD @DrKateDibble @DrDawnHershman

From a #CancerSurvivorship-focused continuing medical education course to practice change implementation: Results of a provider survey 👉pubmed.ncbi.nlm.nih.gov/4173… @DrKateDibble @AnnPartridgeMD @DrN_CancerPCP @jcansurv

📣 Now available as open access on @JCO_ASCO: our analysis on extended endocrine therapy (ET) in premenopausal pts with eBC after 5y of LHRHa. ascopubs.org/doi/10.1200/JCO… Which are the pros and cons of extended ET in this setting? 🤔 A thread 🧵1/ @IEOufficiale @DFCI_BreastOnc

Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer: A Cohort Study ascopubs.org/doi/10.1200/JCO… This cohort analysis evaluated extended endocrine therapy 💊after five years of LHRH agonists in premenopausal women with node-positive, hormone receptor–positive early #BreastCancer . Among 501 patients, extended therapy significantly improved invasive and distant recurrence-free survival compared with stopping therapy. Five-year invasive disease–free survival was 85% versus 78%. Benefits occurred without increased fractures or major cardiovascular events, supporting extended therapy as a clinically meaningful strategy for high-risk young patients after treatment. @ValenzaCarmine @darioT_ @PierPaoloBG @bianchitaM @DrKateDibble @elisabettasabet @curijoey @AnnPartridgeMD

So honored to work with this extraordinary group!

Happy to be part of this incredible family! ❤️❤️ @DFCI_BreastOnc @DanaFarber @AnnPartridgeMD @GuiNaderMarta @DrKateDibble

Come join our team! Clinical Research Coordinator (CRC) - Young Women's Program (#Boston, Massachusetts) #job social.icims.com/viewjob/pt1… @DFCI_BreastOnc

Check out this recent study from @DanaFarber's Young & Strong Program looking at engagement with programmatic electronic communications among young adults with #BreastCancer. 👉pubmed.ncbi.nlm.nih.gov/4032… @DrKateDibble @KimiaSorouriMD @aj_wiswell @AnnPartridgeMD #AYA #PatientEducation

New pub --> Engagement with Programmatic Electronic Communications among YAs with Breast Cancer published in @MASCC_JSCC. Using @DFCI_BreastOnc Young & Strong program e-comms, we aim to understand engagement & interest by topic offered. rdcu.be/ekNK1 @AnnPartridgeMD

New pub --> Associations between CAHPS scores of patient care experiences and breast cancer survival among senior female survivors: A SEER-CAHPS analysis, the last of my postdoc work! tandfonline.com/doi/full/10.…

Congratulations to our @DFCI_BreastOnc providers who were named as #TopDoctors in @BostonMagazine's annual list! ✨Dr. Caroline Block @CBlockMD ✨Dr. Craig Bunnell @bunnell_craig ✨Dr. Harold Burstein @DrHBurstein ✨Dr. Judy Garber @judygarber5 ✨Dr. Michael Hassett ✨Dr. Jennifer Ligibel ✨Dr. Nancy Lin @nlinmd ✨Dr. Filipa Lynce @filipalynce ✨Dr. Erica Mayer @elmayermd ✨Dr. Ann Partridge @AnnPartridgeMD ✨Dr. Geoffrey Shapiro @GShapiroMDPhD ✨Dr. Laura Dominici @dr_laurad ✨Dr. Tari King @tarikingmd ✨Dr. Beth Mittendorf @EMittendorfMD ✨Dr. Faina Nakhlis ✨Dr. Esther Rhei ✨Dr. Jennifer Bellon @jenniferbellon2 ✨Dr. Laura Warren @lwarrenMD ✨ Dr. Stuart Schnitt @SchnittStuart

Miss you all!!!!

Unveiling insights into Oncotype DX recurrence scores and their prognostic value in young patients with ER breast cancer diagnosed during pregnancy or postpartum @AnnPartridgeMD @DFCI_BreastOnc

New protocol pub on the YES intervention published in @BioMedCentral —> link.springer.com/content/pd… @AnnPartridgeMD @ShoshRosenberg @DFCI_BreastOnc

#SABCS24 POSTER SESSION | P2-01-06 | Supportive care concerns of young women living with #MetastaticBreastCancer from an ongoing prospective virtual intervention. @DrKateDibble @ShoshRosenberg @PhilipPoorvu @drsarahsam @nlinmd @AnnPartridgeMD

#SABCS24 POSTER SESSION | P1-03-30 | Genomic risk score distribution and outcomes of patients with early-stage #BreastCancer diagnosed during pregnancy. @GuiNaderMarta @DrKateDibble @elmayermd @PhilipPoorvu @KathrynRuddyMD @nellage @DrEricWiner @AnnPartridgeMD